Mapping disease networks.Bringing complex biology into focus.Revolutionizing drug discovery.

Deep insights into underlying disease biology remains elusive, slowing innovation. Rezo is pioneering an integrated approach to drug discovery that leverages cutting-edge technologies to bring disease networks into focus, enabling the pinpointing of targets and the development of therapies with unprecedented clarity and speed.

About Us

Rezo’s Differentiated Approach to Tackling Disease

Rezo is tackling some of the most difficult challenges in medicine by mapping and therapeutically targeting networks that go awry in disease. Starting with genomic data, Rezo integrates distinct, unbiased technologies coupled with artificial intelligence to identify targets and therapies. Based on pioneering work from the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco, our mission is to break the mold in traditional drug development through the convergence of distinct scientific disciplines and insights from academia and industry. Rezo’s proprietary platform is applicable across a broad range of diseases. The initial focus of Rezo is in oncology, with plans to explore additional therapeutic areas through collaborations and partnerships.


World class scientists, investors, and board members drive fearless innovation. Our global network of academic and industry scientists enables the convergence of cutting-edge scientific disciplines and unique collaborations.

Integrated Platform

Fully integrated technologies elucidating protein-protein interactions, genetic interactions, chemical biology, structural biology, and bioinformatics have applications across disease areas.


Using network biology coupled with advanced artificial intelligence and machine learning for rapid, elevated, and thorough data integration and analysis.

Our Team

Rezo’s leadership consists of world-renowned scientists, proven drug developers, and experienced executives united by their mission to pioneer a new approach to better medicine.


nevan krogan
Nevan Krogan, Ph.D.
Co-Founder and Chief Executive Officer
kevan shokat
Kevan Shokat, Ph.D.
george scangos
George Scangos, Ph.D.
Co-Founder and Board Chairperson
sourav bandyopadhyay
Sourav Bandyopadhyay, Ph.D.
Co-Founder and Chief Scientific Officer
natalia jura
Natalia Jura, Ph.D.
norbert bischofberger
Norbert Bischofberger, Ph.D.
Co-Founder and Board Member
peggy ackerberg
Peggy Ackerberg
Executive Assistant
Chris Adams
Chris Adams, Ph.D.
Director of Proteomics
ali bashir
Ali Bashir, Ph.D.
Head of Computational Biology and AI
hannes braberg
Hannes Braberg, Ph.D.
Principal Scientist,
Computational Biology
hannes braberg
Todd Daigle
Facilities & Operations Manager
krystal fontaine
Krystal Fontaine, Ph.D.
Head of R&D Operations and Program Management
keelan guiley
Keelan Guiley, Ph.D.
Principal Scientist and Associate Director, Protein Sciences
Kevin Hu
Kevin Hu, Ph.D.
Scientist II
Deidre Johns
Deidre Johns, Ph.D.
Head of Chemistry
Shea King
Shea King, M.B.A.
Head of Operations
Alejandro Ramirez
Alejandro Ramirez
Senior Research Associate II and R&D Operations Specialist
Katherine Schutt
Katherine Schutt, Ph.D.
Scientist II, Discovery Biology & Target Validation
Simranjit Singh
Simranjit Singh, Ph.D. 
Scientist I, Discovery Biology & Target Validation
jenna triplett
Jenna Triplett
Senior Research Associate, Biochemistry and Protein Sciences

Board of Directors


a16z logo

sr one logo

norwest logo

alexandria venture logo

hawktail logo

lilly logo

Liquid2 logo

sv angel logo

ucsf logo


Rezo’s groundbreaking approach integrates data from multiple advanced technologies to give a more complete and accurate view of mechanisms that cause disease. Capitalizing on the abundance of genomic data available and recognizing the inherent limitations in translating sequence to function, the company’s Sequence to Systems to Drugs (SSD) platform is able to map molecular disease networks and identify new therapies by integrating the most recent and cutting-edge approaches in proteomics, genetics, structural biology, chemistry and bioinformatics.

The platform is broadly applicable and has already generated important findings across a variety of conditions from cancer to infectious disease, including critical efforts in understanding SARS-Cov-2 during the COVID-19 pandemic. 

REZO platform graphic

REZO platform graphic

Integrating sophisticated technologies under one platform enables integration and cross-fertilization, yielding richer datasets and novel therapies


At the core, we are innovators equipping ourselves with state-of-the-art technologies and curious minds to revolutionize drug discovery and enable better health through better therapies. We recognize that realizing our mission depends as much on our people as it does on our science. We're cultivating a culture of collaboration, respect, honesty, and responsibility, where contributing to your team’s success is valued as highly as individual achievements.  If you’re passionate about team science and breaking down barriers to progress in drug development, please consider joining us!

View Job Listings